Last updated: April 25, 2026
Who Supplies Carisoprodol for Pharmaceuticals and Generics?
Carisoprodol is a controlled, centrally acting skeletal muscle relaxant. In the drug-product supply chain, “suppliers” typically break into three buckets: API manufacturers (carisoprodol active pharmaceutical ingredient), finished-dose manufacturers (carisoprodol tablets), and chemical/solvent and excipient suppliers used for formulation. Public, verifiable supplier lists for carisoprodol are limited because (1) it is tightly regulated, (2) it appears under multiple listings depending on jurisdiction and packaging strength, and (3) many upstream players disclose only through regulatory submissions rather than consumer-facing catalogs.
This response therefore focuses on hard, documentable supplier channels used in pharma procurement for carisoprodol: regulatory reference listings and manufacturer registries that identify specific legal entities.
What are the procurement-relevant supplier categories for carisoprodol?
-
API suppliers (carisoprodol substance)
Companies that produce or sell carisoprodol API for generic tablet manufacturing.
-
Finished-dose tablet manufacturers (carisoprodol tablets)
Companies that make carisoprodol tablets under NDA/ANDA or contract manufacturing agreements (CMOs/CDMOs).
-
Regulated sourcing and documentation pathway
For controlled substances, procurement typically requires traceable manufacturing records, controlled-substance handling compliance, and regulatory dossier linkage (e.g., DMF/ASMF holdings where applicable).
Which API suppliers are identified in regulator-facing databases?
The most procurement-relevant supplier identifiers for API are those tied to drug-substance regulatory filings (DMF/ASMF) and inspection history in the jurisdictions where the product is marketed. For carisoprodol, the supply base is not consistently listed in public-facing catalogs at the level of “supplier of record” for API, and many listings are paywalled or jurisdiction-specific.
Which finished-dose suppliers are commonly associated with carisoprodol tablets?
Carisoprodol tablet brands and generics are manufactured and marketed by specific companies that hold marketing authorization in each country, with manufacturing sometimes performed by contract sites. Finished-dose manufacturers can be identified by:
- national drug approval databases (marketing authorization holders and manufacturers),
- labeler information on local product listings,
- and regulatory inspection records linked to manufacturing sites.
Because “carisoprodol suppliers” varies by country, tablet strength (e.g., 250 mg and 350 mg in common markets), and whether the buyer needs API or finished goods, procurement must map the exact target market first. Without that market anchor, supplier lists risk being incomplete or wrong.
What supplier information can be verified through public procurement registries?
For high-stakes R&D and sourcing decisions, buyers generally verify suppliers via:
- Regulatory substance listings (API DMF/ASMF holder where available)
- Drug product authorization registers (manufacturing site and marketing authorization holder)
- Controlled substance licensing records (where available to the public)
- GxP inspection outcomes (site-level quality status)
In practice, buyers use these sources to confirm:
- manufacturing site address and legal entity,
- quality system readiness (GMP status),
- and chain-of-custody controls for controlled substances.
Key procurement action points for sourcing carisoprodol
Carisoprodol sourcing is operationally constrained by control status. Procurement must be designed to satisfy controlled substance handling and GMP documentation expectations.
Supplier qualification checklist (what procurement should require)
-
GMP compliance evidence
- valid GMP certificate for the API and/or finished dosage form
- inspection history and remediation status for the relevant site
-
Regulatory dossier linkage
- proof of inclusion in relevant drug submissions (where applicable)
- quality module availability (e.g., specifications, analytical methods)
-
Controlled substance handling
- licensing and secure storage controls for carisoprodol
- validated logistics and traceability documentation
-
Quality agreement terms
- change control notification for manufacturing process changes
- batch release responsibility and CoA content requirements
Commercial structuring that affects supplier selection
- API vs finished dose: API sourcing requires stronger controls for substance handling and analytical release; finished-dose sourcing requires tablet manufacturing GMP and packaging controls.
- Strength and dosage form: even for the “same” molecule, approvals and manufacturing equipment differ by strength and tablet formulation.
- Market authorization: supplier eligibility can be limited by which entity holds authorization for the target market.
Key Takeaways
- Carisoprodol supplier identification depends on whether the buyer needs API or finished-dose tablets and on the jurisdiction where the product will be sold or used.
- Procurement for carisoprodol is operationally constrained by controlled-substance handling, GMP site qualification, and regulatory dossier linkage rather than by generic “supplier catalogs.”
- The most defensible approach is supplier selection through regulatory registers and submission-linked listings, then contract qualification via quality agreements and controlled-substance compliance.
FAQs
1) Do carisoprodol API suppliers differ from finished-dose tablet manufacturers?
Yes. API producers and finished-dose manufacturers are often different legal entities and different GMP sites, even when the same company group is involved.
2) What documentation is typically required to buy carisoprodol as an API?
Buyers generally need GMP evidence, controlled-substance handling compliance, and dossier-linked quality specifications and analytical methods.
3) Why can’t a single universal “supplier list” be used worldwide?
Carisoprodol availability and the legal entity allowed to market or manufacture varies by country, including marketing authorization holders and manufacturing site assignments.
4) Are carisoprodol suppliers listed in public places like chemical marketplaces?
Some marketplaces list product availability, but procurement-grade verification usually requires regulatory evidence, GMP status, and controlled-substance traceability.
5) What is the fastest route to qualify a supplier for carisoprodol?
Regulatory-site identification first, then GxP document review (GMP, CoA templates, specs, methods), then controlled-substance logistics and quality agreement execution.
References
[1] U.S. Drug Enforcement Administration (DEA). Controlled Substances. https://www.dea.gov/controlled-substances
[2] U.S. Food and Drug Administration (FDA). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
[3] World Health Organization (WHO). WHO Model List of Essential Medicines. https://www.who.int/teams/health-product-and-policy-standards/standards-and-specifications/norms-and-standards-for-health-products/essential-medicines
